APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-angiogenic Ophthalmic Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-angiogenic Ophthalmic Agent Market Outlook and Growth Opportunities 2026

22 December 2025209 pages

Choose your research edition.

Industry ResearchAnti-angiogenic Ophthalmic Agent Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-angiogenic Ophthalmic Agent Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Anti-angiogenic Ophthalmic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-angiogenic Ophthalmic Agent Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-angiogenic Ophthalmic Agent Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Anti-angiogenic Ophthalmic Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-angiogenic Ophthalmic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-angiogenic Ophthalmic Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-angiogenic Ophthalmic Agent market include Sun Pharma, Johnson & Johnson, Novartis AG, Gilead Sciences, Inc., Pfizer, Daiichi Sankyo, Bayer AG, The Geuder Group, MORCHER GmbH and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-angiogenic Ophthalmic Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-angiogenic Ophthalmic Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-angiogenic Ophthalmic Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-angiogenic Ophthalmic Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-angiogenic Ophthalmic Agent Segment by Company

Sun Pharma

Johnson & Johnson

Novartis AG

Gilead Sciences, Inc.

Pfizer

Daiichi Sankyo

Bayer AG

The Geuder Group, MORCHER GmbH

Shanghai Pharmaceuticals

Santen Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

Otsuka Pharmaceutical Co. Ltd

Novamedika

Medicom Health care

Implant ophthalmic products GmbH

Genentech, Inc.

Eyetech Inc.

ERC Labs

Becton, Dickinson and Company

Allergan plc

Anti-angiogenic Ophthalmic Agent Segment by Type

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Macular Edema

Macular Degeneration

Anti-angiogenic Ophthalmic Agent Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Anti-angiogenic Ophthalmic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-angiogenic Ophthalmic Agent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-angiogenic Ophthalmic Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-angiogenic Ophthalmic Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-angiogenic Ophthalmic Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-angiogenic Ophthalmic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-angiogenic Ophthalmic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-angiogenic Ophthalmic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-angiogenic Ophthalmic Agent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-angiogenic Ophthalmic Agent industry.

Chapter 3: Detailed analysis of Anti-angiogenic Ophthalmic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-angiogenic Ophthalmic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-angiogenic Ophthalmic Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-angiogenic Ophthalmic Agent Industry Trends Table 2. Anti-angiogenic Ophthalmic Agent Industry Drivers Table 3. Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges Table 4. Anti-angiogenic Ophthalmic Agent Industry Restraints Table 5. Global Anti-angiogenic Ophthalmic Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-angiogenic Ophthalmic Agent Revenue Share by Company (2021-2026) Table 7. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Company (k units) & (2021-2026) Table 8. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Company (2021-2026) Table 9. Global Anti-angiogenic Ophthalmic Agent Average Price (US$/unit) of Company (2021-2026) Table 10. Global Anti-angiogenic Ophthalmic Agent Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-angiogenic Ophthalmic Agent Key Company Manufacturing Base & Headquarters Table 12. Global Anti-angiogenic Ophthalmic Agent Company, Product Type & Application Table 13. Global Anti-angiogenic Ophthalmic Agent Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-angiogenic Ophthalmic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diabetic Retinopathy Table 18. Significant Companies of Myopic Choroidal Neovascularization Table 19. Significant Companies of Macular Edema Table 20. Significant Companies of Macular Degeneration Table 21. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2021-2026) & (k units) Table 23. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2027-2032) & (k units) Table 24. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Type (2021-2026) Table 25. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Type (2027-2032) Table 26. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Type (2021-2026) Table 30. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Pharmacies Table 32. Significant Companies of Online Pharmacies Table 33. Significant Companies of Retail Pharmacies Table 34. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2021-2026) & (k units) Table 36. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2027-2032) & (k units) Table 37. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Application (2021-2026) Table 38. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Application (2027-2032) Table 39. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Application (2021-2026) Table 43. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Application (2027-2032) Table 44. Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2026) & (k units) Table 46. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2021-2026) Table 47. Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032) & (k units) Table 48. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region (2027-2032) Table 49. Global Anti-angiogenic Ophthalmic Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Region (2021-2026) Table 52. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Region (2027-2032) Table 54. Global Anti-angiogenic Ophthalmic Agent Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Anti-angiogenic Ophthalmic Agent Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Anti-angiogenic Ophthalmic Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026) & (k units) Table 59. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2021-2026) Table 60. Global Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032) & (k units) Table 61. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Country (2027-2032) Table 62. Global Anti-angiogenic Ophthalmic Agent Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Anti-angiogenic Ophthalmic Agent Sales Value Market Share by Country (2021-2026) Table 64. Global Anti-angiogenic Ophthalmic Agent Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Anti-angiogenic Ophthalmic Agent Sales Value Market Share by Country (2027-2032) Table 66. Sun Pharma Company Information Table 67. Sun Pharma Business Overview Table 68. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio Table 70. Sun Pharma Recent Development Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Novartis AG Company Information Table 77. Novartis AG Business Overview Table 78. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 80. Novartis AG Recent Development Table 81. Gilead Sciences, Inc. Company Information Table 82. Gilead Sciences, Inc. Business Overview Table 83. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 85. Gilead Sciences, Inc. Recent Development Table 86. Pfizer Company Information Table 87. Pfizer Business Overview Table 88. Pfizer Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio Table 90. Pfizer Recent Development Table 91. Daiichi Sankyo Company Information Table 92. Daiichi Sankyo Business Overview Table 93. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio Table 95. Daiichi Sankyo Recent Development Table 96. Bayer AG Company Information Table 97. Bayer AG Business Overview Table 98. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio Table 100. Bayer AG Recent Development Table 101. The Geuder Group, MORCHER GmbH Company Information Table 102. The Geuder Group, MORCHER GmbH Business Overview Table 103. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 105. The Geuder Group, MORCHER GmbH Recent Development Table 106. Shanghai Pharmaceuticals Company Information Table 107. Shanghai Pharmaceuticals Business Overview Table 108. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio Table 110. Shanghai Pharmaceuticals Recent Development Table 111. Santen Pharmaceutical Co., Ltd. Company Information Table 112. Santen Pharmaceutical Co., Ltd. Business Overview Table 113. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 115. Santen Pharmaceutical Co., Ltd. Recent Development Table 116. Regeneron Pharmaceuticals, Inc. Company Information Table 117. Regeneron Pharmaceuticals, Inc. Business Overview Table 118. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 120. Regeneron Pharmaceuticals, Inc. Recent Development Table 121. Otsuka Pharmaceutical Co. Ltd Company Information Table 122. Otsuka Pharmaceutical Co. Ltd Business Overview Table 123. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio Table 125. Otsuka Pharmaceutical Co. Ltd Recent Development Table 126. Novamedika Company Information Table 127. Novamedika Business Overview Table 128. Novamedika Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio Table 130. Novamedika Recent Development Table 131. Medicom Health care Company Information Table 132. Medicom Health care Business Overview Table 133. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio Table 135. Medicom Health care Recent Development Table 136. Implant ophthalmic products GmbH Company Information Table 137. Implant ophthalmic products GmbH Business Overview Table 138. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio Table 140. Implant ophthalmic products GmbH Recent Development Table 141. Genentech, Inc. Company Information Table 142. Genentech, Inc. Business Overview Table 143. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 145. Genentech, Inc. Recent Development Table 146. Eyetech Inc. Company Information Table 147. Eyetech Inc. Business Overview Table 148. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio Table 150. Eyetech Inc. Recent Development Table 151. ERC Labs Company Information Table 152. ERC Labs Business Overview Table 153. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio Table 155. ERC Labs Recent Development Table 156. Becton, Dickinson and Company Company Information Table 157. Becton, Dickinson and Company Business Overview Table 158. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio Table 160. Becton, Dickinson and Company Recent Development Table 161. Allergan plc Company Information Table 162. Allergan plc Business Overview Table 163. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio Table 165. Allergan plc Recent Development Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. Anti-angiogenic Ophthalmic Agent Distributors List Table 169. Anti-angiogenic Ophthalmic Agent Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. Anti-angiogenic Ophthalmic Agent Product Image Figure 2. Global Anti-angiogenic Ophthalmic Agent Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-angiogenic Ophthalmic Agent Sales (2021-2032) & (k units) Figure 5. Global Anti-angiogenic Ophthalmic Agent Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Anti-angiogenic Ophthalmic Agent Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diabetic Retinopathy Image Figure 10. Myopic Choroidal Neovascularization Image Figure 11. Macular Edema Image Figure 12. Macular Degeneration Image Figure 13. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Type (2021-2032) Figure 16. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Anti-angiogenic Ophthalmic Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Type (2021-2032) Figure 19. Hospital Pharmacies Image Figure 20. Online Pharmacies Image Figure 21. Retail Pharmacies Image Figure 22. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Application (2021-2032) Figure 25. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Anti-angiogenic Ophthalmic Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Application (2021-2032) Figure 28. Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Anti-angiogenic Ophthalmic Agent Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Anti-angiogenic Ophthalmic Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032) & (US$ Million) Figure 33. North America Anti-angiogenic Ophthalmic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Anti-angiogenic Ophthalmic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032) & (US$ Million) Figure 39. South America Anti-angiogenic Ophthalmic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Anti-angiogenic Ophthalmic Agent Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Anti-angiogenic Ophthalmic Agent Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Diabetic Retinopathy
  • Myopic Choroidal Neovascularization
  • Macular Edema
  • Macular Degeneration
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Sun Pharma
  • Johnson & Johnson
  • Novartis AG
  • Gilead Sciences, Inc.
  • Pfizer
  • Daiichi Sankyo
  • Bayer AG
  • The Geuder Group, MORCHER GmbH
  • Shanghai Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co. Ltd
  • Novamedika
  • Medicom Health care
  • Implant ophthalmic products GmbH
  • Genentech, Inc.
  • Eyetech Inc.
  • ERC Labs
  • Becton, Dickinson and Company
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032)
  4. 1.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-angiogenic Ophthalmic Agent Market Dynamics
  1. 2.1 Anti-angiogenic Ophthalmic Agent Industry Trends
  2. 2.2 Anti-angiogenic Ophthalmic Agent Industry Drivers
  3. 2.3 Anti-angiogenic Ophthalmic Agent Industry Opportunities and Challenges
  4. 2.4 Anti-angiogenic Ophthalmic Agent Industry Restraints
3 Anti-angiogenic Ophthalmic Agent Market by Company
  1. 3.1 Global Anti-angiogenic Ophthalmic Agent Company Revenue Ranking in 2025
  2. 3.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Company (2021-2026)
  3. 3.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-angiogenic Ophthalmic Agent Average Price by Company (2021-2026)
  5. 3.5 Global Anti-angiogenic Ophthalmic Agent Company Ranking (2024-2026)
  6. 3.6 Global Anti-angiogenic Ophthalmic Agent Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-angiogenic Ophthalmic Agent Company Product Type and Application
  8. 3.8 Global Anti-angiogenic Ophthalmic Agent Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-angiogenic Ophthalmic Agent Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-angiogenic Ophthalmic Agent Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-angiogenic Ophthalmic Agent Market by Type
  1. 4.1 Anti-angiogenic Ophthalmic Agent Type Introduction
  2. 4.1.1 Diabetic Retinopathy
  3. 4.1.2 Myopic Choroidal Neovascularization
  4. 4.1.3 Macular Edema
  5. 4.1.4 Macular Degeneration
  6. 4.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type
  7. 4.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Anti-angiogenic Ophthalmic Agent Sales Value by Type
  11. 4.3.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2021-2032)
  13. 4.3.3 Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Type (2021-2032)
5 Anti-angiogenic Ophthalmic Agent Market by Application
  1. 5.1 Anti-angiogenic Ophthalmic Agent Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application
  6. 5.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anti-angiogenic Ophthalmic Agent Sales Value by Application
  10. 5.3.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anti-angiogenic Ophthalmic Agent Sales Value Share by Application (2021-2032)
6 Anti-angiogenic Ophthalmic Agent Regional Sales and Value Analysis
  1. 6.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-angiogenic Ophthalmic Agent Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-angiogenic Ophthalmic Agent Sales by Region (2027-2032)
  5. 6.3 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-angiogenic Ophthalmic Agent Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032)
  12. 6.6.2 North America Anti-angiogenic Ophthalmic Agent Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-angiogenic Ophthalmic Agent Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-angiogenic Ophthalmic Agent Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032)
  21. 6.9.2 South America Anti-angiogenic Ophthalmic Agent Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value Share by Country, 2025 VS 2032
7 Anti-angiogenic Ophthalmic Agent Country-level Sales and Value Analysis
  1. 7.1 Global Anti-angiogenic Ophthalmic Agent Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-angiogenic Ophthalmic Agent Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-angiogenic Ophthalmic Agent Sales by Country (2027-2032)
  6. 7.4 Global Anti-angiogenic Ophthalmic Agent Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-angiogenic Ophthalmic Agent Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-angiogenic Ophthalmic Agent Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-angiogenic Ophthalmic Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharma
  2. 8.1.1 Sun Pharma Company Information
  3. 8.1.2 Sun Pharma Business Overview
  4. 8.1.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Portfolio
  6. 8.1.5 Sun Pharma Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 Gilead Sciences, Inc.
  20. 8.4.1 Gilead Sciences, Inc. Company Information
  21. 8.4.2 Gilead Sciences, Inc. Business Overview
  22. 8.4.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  24. 8.4.5 Gilead Sciences, Inc. Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Daiichi Sankyo
  32. 8.6.1 Daiichi Sankyo Company Information
  33. 8.6.2 Daiichi Sankyo Business Overview
  34. 8.6.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Portfolio
  36. 8.6.5 Daiichi Sankyo Recent Developments
  37. 8.7 Bayer AG
  38. 8.7.1 Bayer AG Company Information
  39. 8.7.2 Bayer AG Business Overview
  40. 8.7.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Portfolio
  42. 8.7.5 Bayer AG Recent Developments
  43. 8.8 The Geuder Group, MORCHER GmbH
  44. 8.8.1 The Geuder Group, MORCHER GmbH Company Information
  45. 8.8.2 The Geuder Group, MORCHER GmbH Business Overview
  46. 8.8.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  48. 8.8.5 The Geuder Group, MORCHER GmbH Recent Developments
  49. 8.9 Shanghai Pharmaceuticals
  50. 8.9.1 Shanghai Pharmaceuticals Company Information
  51. 8.9.2 Shanghai Pharmaceuticals Business Overview
  52. 8.9.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Portfolio
  54. 8.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 8.10 Santen Pharmaceutical Co., Ltd.
  56. 8.10.1 Santen Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Santen Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Portfolio
  60. 8.10.5 Santen Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Regeneron Pharmaceuticals, Inc.
  62. 8.11.1 Regeneron Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Regeneron Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  66. 8.11.5 Regeneron Pharmaceuticals, Inc. Recent Developments
  67. 8.12 Otsuka Pharmaceutical Co. Ltd
  68. 8.12.1 Otsuka Pharmaceutical Co. Ltd Company Information
  69. 8.12.2 Otsuka Pharmaceutical Co. Ltd Business Overview
  70. 8.12.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Portfolio
  72. 8.12.5 Otsuka Pharmaceutical Co. Ltd Recent Developments
  73. 8.13 Novamedika
  74. 8.13.1 Novamedika Company Information
  75. 8.13.2 Novamedika Business Overview
  76. 8.13.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Portfolio
  78. 8.13.5 Novamedika Recent Developments
  79. 8.14 Medicom Health care
  80. 8.14.1 Medicom Health care Company Information
  81. 8.14.2 Medicom Health care Business Overview
  82. 8.14.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Portfolio
  84. 8.14.5 Medicom Health care Recent Developments
  85. 8.15 Implant ophthalmic products GmbH
  86. 8.15.1 Implant ophthalmic products GmbH Company Information
  87. 8.15.2 Implant ophthalmic products GmbH Business Overview
  88. 8.15.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Portfolio
  90. 8.15.5 Implant ophthalmic products GmbH Recent Developments
  91. 8.16 Genentech, Inc.
  92. 8.16.1 Genentech, Inc. Company Information
  93. 8.16.2 Genentech, Inc. Business Overview
  94. 8.16.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  96. 8.16.5 Genentech, Inc. Recent Developments
  97. 8.17 Eyetech Inc.
  98. 8.17.1 Eyetech Inc. Company Information
  99. 8.17.2 Eyetech Inc. Business Overview
  100. 8.17.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Portfolio
  102. 8.17.5 Eyetech Inc. Recent Developments
  103. 8.18 ERC Labs
  104. 8.18.1 ERC Labs Company Information
  105. 8.18.2 ERC Labs Business Overview
  106. 8.18.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Portfolio
  108. 8.18.5 ERC Labs Recent Developments
  109. 8.19 Becton, Dickinson and Company
  110. 8.19.1 Becton, Dickinson and Company Company Information
  111. 8.19.2 Becton, Dickinson and Company Business Overview
  112. 8.19.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Portfolio
  114. 8.19.5 Becton, Dickinson and Company Recent Developments
  115. 8.20 Allergan plc
  116. 8.20.1 Allergan plc Company Information
  117. 8.20.2 Allergan plc Business Overview
  118. 8.20.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Portfolio
  120. 8.20.5 Allergan plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-angiogenic Ophthalmic Agent Value Chain Analysis
  2. 9.1.1 Anti-angiogenic Ophthalmic Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-angiogenic Ophthalmic Agent Sales Mode & Process
  6. 9.2 Anti-angiogenic Ophthalmic Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-angiogenic Ophthalmic Agent Distributors
  9. 9.2.3 Anti-angiogenic Ophthalmic Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst